newsfilter
← Latest News
GlobeNewswire·

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma